| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Fluocinolone acetonide intravitreal implant |
| Brand | Iluvien® |
| Indication | For the treatment of vision impairment associated with chronic diabetic macular oedema (DMO) considered insufficiently responsive to available therapies. |
| Assessment Process | |
| Rapid review commissioned | 15/02/2016 |
| Rapid review completed | 01/03/2016 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Not Recommended. |